Nifty
:
24834.85
Sensex
:
81332.72
428.75 (1.76%)
1292.92 (1.62%)
Nifty
Sensex
:
:
24834.85
81332.72
428.75 (1.76%)
1292.92 (1.62%)

Wanbury Ltd.

Pharmaceuticals & Drugs

Rating :
60/99

BSE: 524212 | NSE: WANBURY

NSE BSE
160.45
05-Jul-2024
  • Open
  • High
  • Low
  • Previous Close
  •  169.23
  •  169.23
  •  159.20
  •  165.23
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  233472
  •  382.58
  •  211.86
  •  49.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 695.51
  • 12.43
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 799.57
  • N/A
  • 32.45

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 39.79%
  • 11.23%
  • 41.41%
  • FII
  • DII
  • Others
  • 0.22%
  • 0.00%
  • 7.35%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 5.01
  • 8.38

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 11.54
  • 8.05

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -15.99
  • -6.22

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 1.60
  • 2.28

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -3.09
  • -4.65
  • -7.19

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.90
  • 12.83
  • 10.82

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Net Sales
139.41
132.97
4.84%
145.50
125.78
15.68%
144.46
123.95
16.55%
146.28
116.94
25.09%
Expenses
121.24
118.81
2.05%
124.35
119.32
4.22%
127.12
118.36
7.40%
132.94
119.98
10.80%
EBITDA
18.16
14.16
28.25%
21.15
6.46
227.40%
17.34
5.60
209.64%
13.35
-3.04
-
EBIDTM
13.03%
10.65%
14.53%
5.13%
12.01%
4.52%
9.12%
-2.60%
Other Income
0.93
-2.06
-
0.69
0.26
165.38%
0.76
0.78
-2.56%
0.62
1.94
-68.04%
Interest
7.46
7.52
-0.80%
8.26
6.63
24.59%
7.67
3.94
94.67%
5.79
3.31
74.92%
Depreciation
3.28
3.07
6.84%
3.32
3.13
6.07%
3.24
3.15
2.86%
3.19
3.03
5.28%
PBT
33.91
0.92
3,585.87%
10.25
-3.04
-
7.19
-0.71
-
4.99
-7.45
-
Tax
0.27
-0.10
-
-0.02
0.23
-
-0.18
0.18
-
0.30
-0.21
-
PAT
33.63
1.02
3,197.06%
10.27
-3.28
-
7.36
-0.89
-
4.69
-7.25
-
PATM
24.13%
0.76%
7.06%
-2.61%
5.10%
-0.72%
3.21%
-6.20%
EPS
10.27
0.31
3,212.90%
3.14
-1.00
-
2.25
-0.27
-
1.43
-2.22
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Sep 14
Net Sales
575.65
499.65
511.19
392.52
367.45
391.37
371.10
433.81
423.26
249.92
661.86
Net Sales Growth
15.21%
-2.26%
30.23%
6.82%
-6.11%
5.46%
-14.46%
2.49%
69.36%
-62.24%
 
Cost Of Goods Sold
302.63
302.59
300.28
221.33
175.74
196.20
174.09
196.97
182.40
119.30
304.08
Gross Profit
273.02
197.06
210.90
171.19
191.72
195.17
197.01
236.83
240.87
130.62
357.78
GP Margin
47.43%
39.44%
41.26%
43.61%
52.18%
49.87%
53.09%
54.59%
56.91%
52.26%
54.06%
Total Expenditure
505.65
476.57
479.45
376.85
389.07
378.00
439.03
415.28
390.89
228.50
637.65
Power & Fuel Cost
-
20.59
18.41
17.13
15.38
14.46
15.26
18.74
18.51
10.05
28.07
% Of Sales
-
4.12%
3.60%
4.36%
4.19%
3.69%
4.11%
4.32%
4.37%
4.02%
4.24%
Employee Cost
-
81.00
74.81
64.15
67.48
75.72
87.10
87.59
85.41
39.57
111.53
% Of Sales
-
16.21%
14.63%
16.34%
18.36%
19.35%
23.47%
20.19%
20.18%
15.83%
16.85%
Manufacturing Exp.
-
11.43
12.66
9.98
13.77
7.98
10.21
15.04
12.34
2.98
14.62
% Of Sales
-
2.29%
2.48%
2.54%
3.75%
2.04%
2.75%
3.47%
2.92%
1.19%
2.21%
General & Admin Exp.
-
23.57
20.58
23.63
28.56
30.47
29.66
34.37
29.80
25.49
47.41
% Of Sales
-
4.72%
4.03%
6.02%
7.77%
7.79%
7.99%
7.92%
7.04%
10.20%
7.16%
Selling & Distn. Exp.
-
21.27
31.31
16.86
19.63
27.41
29.49
42.43
34.19
15.15
62.46
% Of Sales
-
4.26%
6.12%
4.30%
5.34%
7.00%
7.95%
9.78%
8.08%
6.06%
9.44%
Miscellaneous Exp.
-
16.12
21.40
23.78
68.51
25.77
93.22
20.14
28.26
15.96
62.46
% Of Sales
-
3.23%
4.19%
6.06%
18.64%
6.58%
25.12%
4.64%
6.68%
6.39%
10.50%
EBITDA
70.00
23.08
31.74
15.67
-21.62
13.37
-67.93
18.53
32.37
21.42
24.21
EBITDA Margin
12.16%
4.62%
6.21%
3.99%
-5.88%
3.42%
-18.31%
4.27%
7.65%
8.57%
3.66%
Other Income
3.00
1.01
5.09
4.75
46.20
11.50
76.70
89.69
1.40
6.48
11.29
Interest
29.18
21.39
20.61
23.07
32.87
39.88
30.86
35.51
31.87
18.62
48.26
Depreciation
13.03
12.38
11.45
9.75
9.68
9.97
10.30
10.32
9.05
4.80
23.37
PBT
56.34
-9.69
4.76
-12.41
-17.97
-24.98
-32.39
62.40
-7.15
4.48
-36.15
Tax
0.37
0.11
-0.35
0.20
0.21
-0.14
-0.38
0.38
0.00
1.27
2.86
Tax Rate
0.66%
-1.07%
-0.43%
-1.61%
0.32%
0.56%
1.17%
0.61%
0.00%
28.35%
-2.29%
PAT
55.95
-10.40
81.47
-12.61
64.46
-24.85
-32.01
62.01
-7.15
3.20
-127.71
PAT before Minority Interest
55.95
-10.40
81.47
-12.61
64.46
-24.85
-32.01
62.01
-7.15
3.20
-127.71
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
9.72%
-2.08%
15.94%
-3.21%
17.54%
-6.35%
-8.63%
14.29%
-1.69%
1.28%
-19.30%
PAT Growth
637.98%
-
-
-
-
-
-
-
-
-
 
EPS
17.11
-3.18
24.91
-3.86
19.71
-7.60
-9.79
18.96
-2.19
0.98
-39.06

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Sep 14
Shareholder's Funds
-32.82
-23.42
-156.24
-143.45
-209.28
-184.68
-153.28
-188.77
-193.94
-191.71
Share Capital
32.71
32.67
25.02
25.00
23.72
23.72
23.22
19.97
19.97
19.97
Total Reserves
-67.15
-57.01
-181.60
-168.66
-233.23
-208.66
-176.50
-220.96
-213.91
-211.68
Non-Current Liabilities
10.81
10.56
84.43
107.74
130.36
105.79
159.92
251.37
298.18
311.67
Secured Loans
0.00
0.00
71.99
99.54
123.03
99.01
153.73
230.92
270.48
279.35
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
13.93
12.07
13.75
11.56
10.69
10.14
9.55
8.76
7.48
6.75
Current Liabilities
320.38
359.77
355.35
311.04
361.60
348.25
401.91
298.61
264.85
259.43
Trade Payables
148.47
179.56
133.77
121.87
112.24
83.13
140.11
86.11
99.15
93.69
Other Current Liabilities
154.53
162.35
200.56
160.75
160.69
178.59
194.50
118.92
85.47
89.17
Short Term Borrowings
13.19
13.21
16.42
24.92
85.21
82.67
63.19
90.60
77.85
74.18
Short Term Provisions
4.19
4.66
4.60
3.50
3.47
3.85
4.12
2.97
2.37
2.39
Total Liabilities
298.37
346.91
283.54
275.33
282.68
269.36
408.55
387.87
395.75
406.05
Net Block
167.11
167.11
167.38
163.90
172.36
178.33
186.34
180.27
164.05
173.67
Gross Block
239.29
226.95
215.98
203.10
202.03
198.61
196.65
325.72
305.65
309.76
Accumulated Depreciation
72.18
59.84
48.59
39.20
29.66
20.28
10.32
145.46
141.60
136.09
Non Current Assets
174.24
173.71
182.28
181.69
184.53
191.66
216.83
223.94
214.65
219.39
Capital Work in Progress
1.61
2.35
11.01
13.89
8.97
10.05
9.58
14.42
18.52
12.96
Non Current Investment
0.01
0.01
0.01
0.01
0.02
0.02
0.03
0.01
0.01
0.01
Long Term Loans & Adv.
5.03
3.80
3.40
3.80
3.11
2.84
20.46
28.98
31.08
32.02
Other Non Current Assets
0.49
0.44
0.46
0.10
0.07
0.41
0.43
0.26
0.99
0.73
Current Assets
122.16
171.24
97.53
93.64
98.15
77.70
191.73
163.93
181.11
186.67
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
21.99
49.73
24.85
12.26
19.33
13.07
34.23
34.61
33.77
35.16
Sundry Debtors
67.98
62.80
34.47
50.79
44.41
29.46
84.66
74.94
98.52
103.19
Cash & Bank
3.93
25.31
11.70
16.70
5.25
6.21
9.37
7.22
12.03
6.69
Other Current Assets
28.26
5.40
23.09
9.42
29.16
28.96
63.47
47.15
36.78
41.63
Short Term Loans & Adv.
23.29
28.00
3.42
4.47
2.69
6.27
37.16
29.41
16.51
21.52
Net Current Assets
-198.22
-188.53
-257.82
-217.41
-263.44
-270.55
-210.19
-134.68
-83.74
-72.76
Total Assets
296.40
344.95
279.81
275.33
282.68
269.36
408.56
387.87
395.76
406.06

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Sep 14
Cash From Operating Activity
19.80
40.52
16.68
44.13
29.73
32.49
43.39
43.05
40.17
68.17
PBT
-10.29
81.13
-12.41
64.67
-24.98
-32.39
62.40
-7.15
4.48
-124.85
Adjustment
37.01
-43.68
33.22
-41.41
42.90
39.71
-37.29
47.85
22.65
191.19
Changes in Working Capital
-6.75
3.24
-3.00
20.90
11.88
26.05
18.33
2.36
13.13
2.07
Cash after chg. in Working capital
19.97
40.69
17.81
44.16
29.80
33.37
43.43
43.07
40.25
68.40
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-0.17
-0.16
-1.13
-0.03
-0.06
-0.89
-0.04
-0.01
-0.08
-0.23
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-8.84
0.59
8.04
63.66
-3.07
-1.39
-13.06
-19.63
-5.33
-6.20
Net Fixed Assets
-11.60
-2.31
-10.00
-5.99
-2.34
-2.43
133.91
-15.98
-1.45
-7.18
Net Investments
0.00
0.00
0.00
0.01
0.00
0.01
-0.02
0.00
0.00
106.06
Others
2.76
2.90
18.04
69.64
-0.73
1.03
-146.95
-3.65
-3.88
-105.08
Cash from Financing Activity
-31.99
-28.58
-17.39
-107.87
-26.78
-33.26
-26.93
-28.07
-29.54
-70.68
Net Cash Inflow / Outflow
-21.03
12.52
7.34
-0.08
-0.13
-2.16
3.39
-4.65
5.29
-8.70
Opening Cash & Equivalents
22.53
10.00
2.66
2.74
2.87
5.03
1.63
6.28
0.99
9.69
Closing Cash & Equivalent
1.49
22.53
10.00
2.66
2.74
2.87
5.03
1.63
6.28
0.99

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Sep 14
Book Value (Rs.)
-10.57
-7.55
-62.60
-57.48
-88.32
-77.97
-66.01
-112.21
-109.34
-108.90
ROA
-3.22%
25.85%
-4.51%
23.10%
-9.00%
-9.44%
15.57%
-1.82%
0.80%
-21.66%
ROE
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
ROCE
29.82%
428.78%
87.61%
444.45%
50.26%
-2.00%
70.48%
15.27%
13.85%
-31.06%
Fixed Asset Turnover
2.18
2.32
1.88
1.83
2.08
2.00
1.70
1.37
0.83
1.50
Receivable days
46.87
34.50
39.45
46.85
32.42
52.61
65.66
72.98
144.54
50.69
Inventory Days
25.70
26.45
17.17
15.54
14.22
21.80
28.32
28.77
49.39
21.08
Payable days
197.84
190.42
210.79
243.11
106.12
125.89
110.93
100.14
182.52
57.27
Cash Conversion Cycle
-125.27
-129.47
-154.17
-180.72
-59.49
-51.47
-16.96
1.60
11.41
14.50
Total Debt/Equity
-1.86
-2.72
-1.02
-1.14
-1.11
-1.19
-1.76
-1.67
-1.74
-1.79
Interest Cover
0.52
4.94
0.46
2.97
0.37
-0.05
2.76
0.78
1.24
-1.59

Annual Reports:

FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014

News Update:


  • Wanbury receives term loan facilities of Rs 60 crore from Tata Capital
    27th Jun 2024, 16:16 PM

    The funds received by the company will be utilized towards the long-term working capital and capex requirement

    Read More
  • USFDA completes inspection at Wanbury’s Patalganga site
    18th Jun 2024, 10:41 AM

    USFDA Inspection started from June 10, 2024 and completed on June 14, 2024 with zero-483 observations

    Read More
  • Wanbury - Quarterly Results
    16th May 2024, 19:26 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.